Simozine

Quick links to important sections

Simozine

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Simozine

Property Description
Active ingredient Cetirizine dihydrochloride
Form Oral tablets, oral solution, syrup
Pharmacological class Second-generation H1-receptor antagonist
General purpose Mitigation of histamine-mediated allergic symptoms
Origin Synthetic compound (Piperazine derivative)

What Type of Medicine is Simozine?

Simozine is a medication entity whose single active component, Cetirizine, classifies it as an antihistamine, specifically a second-generation H1-receptor antagonist. Its fundamental purpose is to mitigate physiological effects caused by the release of histamine in the body, serving as an effective agent for managing allergic responses.

The identity of Simozine is rooted in its pharmacological profile: Cetirizine is a potent and selective antagonist of peripheral H1-receptors. The selective action of this compound is clinically recognized for reducing the physical manifestations of the body's overreaction to allergens. This high receptor selectivity is a differentiating factor that allows the drug to counteract the effects of histamine while maintaining a general over-the-counter (OTC) status in many regions, underscoring its established safety profile for general use.

Simozine's Composition and Origin

The composition of Simozine centers on the active ingredient, Cetirizine dihydrochloride, which is a highly specialized, synthetic compound derived from the piperazine chemical structure. It is chemically defined as a Carboxy-hydroxyethyl-piperazine derivative, confirming that the drug is manufactured entirely through chemical synthesis.

As a single-component product (monotherapy), Simozine contains Cetirizine dihydrochloride alongside standard pharmaceutical excipients necessary for stability and administration. For instance, the liquid formulations often include specific flavoring agents to enhance palatability for the pediatric patient group, where liquid administration is common.

Available Preparations of Simozine

Simozine is supplied in several common dosage forms suitable for oral administration, offering options that cater to the needs of the general patient population. The primary preparations available include film-coated tablets, as well as liquid formulations such as an oral solution or a syrup.

These different dosage forms ensure therapeutic access and flexibility for ingestion. The inclusion of measuring accessories with the oral solution is designed to simplify the administration process, while guaranteeing that each preparation contains the same foundational active substance, Cetirizine dihydrochloride.

What side effects are possible with Simozine?

Simozine is classified as a chemical agent, not a human therapeutic drug. Safety and side effect information is based on governmental regulatory hazard communication and toxicology reports from bodies like the U.S. EPA and OSHA.

Potential Adverse Reactions and Toxicological Data

The most significant risks identified by regulatory agencies include the potential for acute and chronic effects across multiple organ systems. Exposure routes include ingestion, inhalation, and skin/eye contact. High-dose acute exposure may cause signs of systemic toxicity such as nausea, vomiting, and gastric distress, while direct contact may cause irritation.

Category Documented Adverse Reactions/Hazards
Systemic/Chronic Toxicity Suspected of causing cancer (Carcinogen Category 2); Potential damage to specific target organs following prolonged or repeated exposure, including the mammary gland, blood, kidney, and central nervous system (CNS).
Acute Local Effects Serious eye irritation; Skin irritation; Mild respiratory irritation. Harmful if swallowed or inhaled.

Population-Specific and Safety Considerations

Regulatory assessments have noted concerns for developmental toxicity and female reproductive toxicity. Simozine is also classified as a potential endocrine disruptor.

Due to its environmental persistence and high toxicity to aquatic organisms, Simozine is officially designated as an environmental hazard. Additionally, certain regulatory bodies classify it as a Toxic Air Contaminant and a Restricted Material, requiring specific safety protocols and handling limitations to minimize potential human and environmental exposure.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of Simozine (Cetirizine) is officially documented by regulatory authorities with a range of clinical and physiological manifestations. These documented signs primarily involve the central nervous system, spanning from states of profound depression, such as somnolence, fatigue, and confusion, to potential states of excitement, including restlessness, irritability, and tremor. Other systemic manifestations officially listed include tachycardia (fast heart rate), diarrhoea, and urinary retention.

A severe overexposure may result in critical outcomes such as stupor or seizure. Official labeling explicitly mandates that immediate medical attention must be sought, typically by contacting a Poison Control Center or emergency services. Regulators require emergency services to be called immediately if the affected individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened.

Management for Cetirizine overexposure is defined as symptomatic and supportive treatment, as regulatory documents confirm that no known specific antidote exists for the compound. Procedurally, gastric lavage may be considered shortly after ingestion. Population-specific regulatory notes indicate that overdose in young children may uniquely present with initial restlessness preceding the onset of drowsiness.

Therapeutic Uses of Simozine

Main Therapeutic Uses

Simozine is primarily utilized in the management of specific gastrointestinal and metabolic conditions. Its main application is to provide relief from symptoms associated with excessive gas production in the digestive tract. By altering the surface tension of gas bubbles within the stomach and intestines, the medication facilitates the easier passage and elimination of gas, which can alleviate physical discomfort and bloating.

Key Indications

  • Relief of Bloating and Pressure: Simozine is used to reduce the sensation of fullness and pressure caused by trapped gas in the upper or lower gastrointestinal tract.
  • Symptomatic Treatment of Flatulence: The medication helps manage frequent or painful flatulence by breaking down large gas pockets into smaller, more easily expelled bubbles.
  • Functional Gastric Disorders: It may be used as an adjunct in treating various functional disorders where gas accumulation contributes to abdominal distress.

Benefits of Treatment

The primary benefit of Simozine is the improvement of digestive comfort. Because the active mechanism is focused on the physical properties of gas bubbles rather than systemic chemical changes in the body, it offers a targeted approach to symptom management.

  • Reduction of Physical Discomfort: By addressing the root cause of gas-related pressure, the medication helps minimize the cramping and sharp pains often associated with intestinal distension.
  • Improvement in Daily Functioning: Reducing chronic bloating and gas can lead to an improved quality of life for individuals dealing with functional digestive issues.
  • Support During Diagnostic Procedures: In certain clinical settings, reducing gas interference can assist in obtaining clearer results during abdominal examinations, such as ultrasounds or endoscopic procedures.

Regulatory References

  1. NIH MedlinePlus overview of Cetirizine

Eligibility and Restrictions for Use

The official regulatory profile for Simozine (Cetirizine) establishes clear limitations on which populations are eligible to use the medicine.

Eligibility Scope

Populations for whom use is contraindicated Age-related eligibility rules
Patients with known hypersensitivity to cetirizine, hydroxyzine, or other piperazine derivatives. Children under 6 years: Tablet formulation is not recommended due to inability to adapt dose.
Patients with severe renal impairment (Creatinine Clearance < 10 mL/min). Infants (6 to 23 months): Eligible for specific indications and liquid formulations in some regions.
Patients with rare hereditary metabolic problems (for specific tablet excipients). Older adults (65 and over): Officially required to ask a doctor before use.

Condition-specific eligibility rules

  • Use is restricted in patients with moderate renal impairment or hepatic impairment, often requiring physician consultation or dose adjustment.
  • Caution is advised for patients with risk factors for urinary retention or those with epilepsy.

Pregnancy and lactation eligibility status

  • Pregnancy: Use is recommended only if clearly needed.
  • Lactation: Use is not recommended.

Connection to the overall eligibility profile: Regulatory documents define who can and cannot use the drug through absolute contraindications based on severe renal dysfunction and drug hypersensitivity. Eligibility is further structured by specific age minimums and physiological conditions like hepatic or moderate renal impairment, which mandate restricted use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Simozine (Cetirizine) has a documented interaction profile focusing on pharmacodynamic effects related to the central nervous system (CNS) and pharmacokinetic effects related to drug clearance, as stated in government regulatory labeling.

Drug–Drug and Drug–Substance Interactions

Interacting Entity/Class Interaction Type Official Regulatory Statement
Central Nervous System (CNS) Depressants Pharmacodynamic Concurrent use with alcohol or other CNS depressants may cause additional reductions in alertness and impairment of performance (additive CNS depressant effect).
Theophylline (400 mg once daily) Pharmacokinetic Co-administration results in a 16% decrease in the clearance of cetirizine.
CYP450 Enzyme System Metabolic No clinically significant interaction documented, as Cetirizine is only metabolized to a limited extent and is not a substrate of the CYP450 enzymes.

Food and Administration Constraints

Food intake is officially documented to affect the rate of absorption. While the total amount of drug absorbed (extent of absorption) remains unchanged, taking Simozine with food decreases the rate of absorption by delaying the time to maximum concentration (Tmax) and reducing the maximum plasma concentration (Cmax). No mandatory timing separation rules are specified in the official labeling.

Population-Specific Interaction Notes

For patients with renal or hepatic impairment, official labeling notes that reduced clearance is expected. This condition-based reduction in clearance requires consideration to prevent increased systemic exposure of Cetirizine.

Mechanism of Action

How Simozine Works: Pharmacodynamic Mechanism

Simozine (Cetirizine) functions primarily as a selective Inverse Agonist, engaging the Peripheral Histamine mathbfH1 Receptors to stabilize their inactive conformational state. This molecular interaction directly suppresses the signaling that endogenous histamine uses to escalate physiological responses. The resulting blockade prevents the histamine-induced increase in the spaces between endothelial cells lining the capillaries.

This core mechanism modulates the plasma fluid leakage into surrounding tissues, which leads to the physiological consequence of reducing local fluid exudation and modulation of glandular hypersecretion in mucosal membranes. Due to its interaction with the P-glycoprotein efflux pump, the drug's activity is largely confined to the periphery. Furthermore, Simozine engages in non- H1-mediated actions, such as inhibiting the recruitment of eosinophils, thereby modulating the late-phase inflammatory response beyond immediate receptor antagonism.

Dosage and Administration Information

How to Use Simozine: Official Administration Guidelines

Simozine, which contains an active ingredient typically classified as a second-generation antihistamine (such as cetirizine or levocetirizine), must be used strictly according to the official instructions.

Administration Scope

Feature Official Instruction
Route of Administration The approved route is oral (by mouth).
Dosing Schedule The standard dose for adults and children 12 years and older is typically 5 mg or 10 mg once daily.
Timing and Meals Simozine may be taken with or without food.
Frequency The medication is taken once daily. It is generally recommended to administer the dose in the evening due to potential drowsiness.
Preparation Tablets should be swallowed whole. Liquid forms (solution or syrup) must be measured accurately using a specific measuring device, such as an oral syringe or dosing cup.

Population-Specific and Missed Dose Rules

Dose Adjustment: The dose must be adjusted for adult patients (12 years and older) with impaired kidney function (renal impairment). The adjusted dose depends on the patient's creatinine clearance. No standard dose adjustment is typically required for isolated hepatic impairment.

Missed Dose: If a dose is missed, it should be taken as soon as the patient remembers. If it is almost time for the next scheduled dose, the missed dose should be skipped, and the patient should resume their regular schedule. The patient must not take two doses to make up for the missed one.

This protocol defines the standardized, non-advisory procedure for taking the medication.

Recent Clinical Evidence

Simozine: Recent Clinical Evidence

This section summarizes the structure of clinical research on Simozine (Cetirizine), focusing strictly on what studies explored and what remains uncertain, without providing medical advice or individual predictions.


Evidence for Allergic Rhinitis and Chronic Hives

Research for allergic rhinitis was studied using short-term, randomized controlled trials (RCTs). These studies examined outcomes related to physical discomfort (nasal and ocular symptoms) using standardized scores, primarily documenting observations over short-term periods, typically up to four weeks. Findings describe patterns measured during these trials. Simozine was also evaluated in studies focusing on chronic hives (urticaria), where researchers monitored outcomes linked to inflammatory or irritative states, such as wheal count and pruritus (itching) intensity. Research exploring doses above the standard studied regimen is an area of uncertainty, as the data is often derived from smaller populations.


Long-Term Data and Special Populations

The full picture regarding long-term effects is not fully established, as the core evidence base relies heavily on short-term data. Follow-up durations were limited in many trials, meaning certainty remains low for the effects of continuous use over multiple years. Studies have included pediatric groups (infants from 6 months of age) for allergic rhinitis, as well as patients who presented with co-existing allergic rhinitis and mild asthma. However, evidence for specific older adult subgroups remains limited, and subgroup findings are uncertain when distinguishing specific response patterns.

Frequently Asked Questions (FAQ)

Common questions about Simozine (FAQ)

Q: What are the most common reasons a doctor prescribes Simozine?

According to the official product information, Simozine is indicated to relieve symptoms related to seasonal and perennial allergic rhinitis, commonly known as hay fever. It is also prescribed to treat the itching and redness that occur due to chronic hives (chronic idiopathic urticaria). These are the main therapeutic uses defined in regulatory documents.

Q: Is Simozine safe to take every day?

Regulatory documents state that the standard therapeutic dose is designed for once-daily administration. It is commonly used for the continuous management of ongoing allergic conditions that require consistent relief. The use of the medication is generally limited to the duration necessary to achieve symptom control.

Q: Are there any known foods or drinks that should be avoided while taking Simozine?

Simozine may be taken with or without food. However, official regulatory documents advise caution regarding alcohol. Concurrent use of Simozine with alcohol may cause an additional increase in drowsiness or reduced alertness.

Q: Does Simozine have a long-term impact on the body?

Clinical studies often focus on short-term use, meaning the full picture of effects over multiple years is not completely established. However, official information indicates that Simozine is used for the continuous management of chronic conditions, such as hives. Its profile differs from that of first-generation antihistamines.

Q: What research studies are available on the long-term use of Simozine?

Studies have examined continuous use of Simozine for extended periods to confirm its effectiveness in controlling persistent allergic symptoms. While the core evidence confirms its use for chronic conditions, the follow-up duration was limited in many key trials. Therefore, the certainty regarding effects over many years of continuous use is still considered low.

Q: Can older adults typically use Simozine safely?

Official labeling states that for adults 65 years and older, a lower dose may be required compared to younger adults. Regulatory documents indicate that older adults are officially required to ask a health professional before use. This caution is due to the way the body processes the medication, as its elimination time can be prolonged in geriatric patients.

Q: What are the signs that Simozine is working?

Studies and official information indicate the drug is working when it effectively mitigates the symptoms it is treating. This may be observed as a reduction in sneezing, runny nose, and itching of the eyes for allergic rhinitis. For chronic hives, signs include a reduction in the itching and the size or number of wheals on the skin.

Q: Is Simozine listed as safe during pregnancy?

Regulatory documents recommend the use of Simozine during pregnancy only if clearly needed and the potential benefits are determined to justify the potential risk to the fetus. Historical data has often categorized it as a medication where animal studies did not show a risk, but sufficient well-controlled studies in pregnant women are lacking.

Q: Does Simozine affect concentration or memory?

As a less-sedating antihistamine, the effect is typically mild, but common side effects can include drowsiness and fatigue. Post-marketing regulatory reports list potential psychiatric effects such as impaired concentration, memory impairment, confusion, and dizziness. These effects are generally uncommon but are included in the official safety profile.

Q: What is the most serious risk associated with taking Simozine?

Serious risks associated with Simozine are rare but documented in regulatory reports. These can include signs of severe allergic reaction (anaphylaxis) and liver problems. Post-marketing reports also list significant mood or behavior changes, such as agitation, aggression, or hallucinations, which are considered critical risks.

Q: How quickly can I expect to notice any effects from taking Simozine?

Studies show that the onset of the antihistaminic effect is generally rapid after a single dose. Most individuals experience the beginning of activity, such as relief from histamine-induced skin reactions, within 20 to 60 minutes.

Q: Is it normal to feel a little dizzy when first starting Simozine?

Yes, regulatory documents indicate that feeling dizzy is a commonly reported side effect, though it is not one of the most frequent. Dizziness is included in the list of adverse reactions reported in clinical trials and post-marketing experience.

Q: Can Simozine cause weight gain or weight loss?

Weight change is not listed among the most common adverse reactions in clinical trials. However, regulatory documents include post-marketing reports of changes in appetite and reports of increased weight associated with its use.

Q: Why do some people need to take Simozine for a long time?

Simozine is often used long-term when treating certain chronic medical conditions. For example, conditions like chronic hives (urticaria) or perennial allergic rhinitis are ongoing, and symptoms require continuous daily management to maintain control.

Q: Does Simozine stay in your system for a while after you stop taking it?

Simozine is designed for once-daily use because it has a relatively long elimination half-life, which is the time it takes for half of the drug to be eliminated from the body. In adults, this half-life averages approximately 8 to 11 hours. The medication is primarily removed from the body unchanged by the kidneys.

Q: Is Simozine considered a Schedule drug or controlled substance?

No, official drug classifications and regulatory bodies confirm that Simozine (cetirizine) is a second-generation antihistamine. It is not classified as a controlled substance under government scheduling acts.

Q: Are there any warnings about Simozine for people with high blood pressure?

Simozine is not primarily contraindicated for high blood pressure. However, post-marketing regulatory reports have included rare cardiovascular-related events, such as changes in blood pressure (both hypertension and hypotension). These effects are not listed among the common side effects.

Q: Does Simozine interact with birth control pills?

Regulatory drug interaction checkers and official product information have found no clinically significant drug-drug interactions between Simozine and hormonal contraceptives. This includes both estrogen- and progestin-containing birth control products.

Q: Is it true that Simozine has been studied for conditions other than its main use?

Yes, studies indicate Simozine has been examined for uses beyond its primary approved indications. Examples include its use as an addition to epinephrine for severe allergic reactions (anaphylaxis) and as a preventive treatment for certain hypersensitivity reactions related to other medication infusions.

Q: Can Simozine cause problems with my stomach?

Yes, regulatory safety data indicates that gastrointestinal issues are among the commonly reported side effects. These problems can include stomach pain (abdominal pain), nausea, and diarrhea.

Q: Is Simozine available as a generic medicine?

Yes, official records from regulatory bodies confirm that Simozine (cetirizine) is available as a generic medication. It is widely distributed as a lower-cost option in addition to its branded form.

Q: Is it possible to develop a tolerance to Simozine over time?

Clinical research and scientific evidence show that users do not develop a pharmacologic tolerance to the antihistamine effects of Simozine. This means that its ability to relieve symptoms typically remains consistent even with continuous daily use over extended periods.

Q: Are there specific symptoms that mean I should stop taking Simozine immediately?

Official emergency information outlines critical signs that require immediate medical attention. These include symptoms of a severe allergic reaction, such as difficulty swallowing or breathing, swelling in or around the mouth, or wheezing.

Q: Can Simozine cause mood changes?

While uncommon, post-marketing reports to regulatory agencies list psychiatric effects associated with Simozine use. These can include mood changes such as agitation, aggression, confusion, depression, and, in rare instances, hallucinations.

Q: Is there a rebound effect if Simozine is stopped suddenly?

Analysis of post-marketing case reports suggests that stopping Simozine suddenly after regular long-term use may rarely result in a temporary rebound effect. This effect usually presents as severe, generalized itching (pruritus).

How should Simozine be stored and disposed of?

How to Store and Dispose of Simozine (Cetirizine)

Official regulatory labeling dictates specific storage and disposal requirements to maintain product stability and ensure safety.

Storage Requirements

  • Temperature and Protection: Store the product below 25 C or not above 30 C. It must be protected from light, moisture, and heat. The label explicitly states Do not freeze.
  • Container and Stability: Keep tablets in the original blister pack and oral solutions in the original container, tightly closed. Liquid forms may have a limited shelf-life (e.g., 4 weeks to 3 months) once opened, and must not be used past the expiration date.
  • Child Safety: Simozine must always be stored out of the sight and reach of children.

Disposal Instructions

  • Environmental Protection: Do not dispose of unused or expired medicine via wastewater or household waste. The proper procedure is to return the unused product to a pharmacy or dispose of it according to local requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Simozine found in:

A-Z Index: